Clinical Trial Search

Primary: Pain Score During the Tampon Test — 4.37; 3.75; 4.04; 4.36 score on a scale — p=0.3630

Primary: Pain Rating Index — 12.3 units on a scale — p=.001

Primary: Global Response Assessment — 5 participants

Primary: Change in Vulvslgesiometer Pain Rating From Baseline to One Month Post-treatment to 6 Months Post-treatment — 6.66; 6.62; 3.21; 3.60 score on a scale

Primary: Deep Dyspareunia Score — 3.08 scores on a scale

Primary: Reduction in Daily Genital Pain. — 2.4; 2.92; 3.42; 2.77 units on a scale — p=0.30

Primary: Tampon Test Pain Intensity — 4.29; 3.96 units on a scale — p=0.07

Primary: Average Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS). — 3.90; 3.51; 2.48; 2.22 score on a scale — p=0.702

Primary: Visible Changes to the Vulva, Vestibule and Vaginal Region on Photography — 8 points improvement on VGTA scale — p=0.05

Primary: Change in Median Dyspareunia Pain Scores After 4 Weeks Using Study Drug — -1.5; -3 score on a scale — p=0.08

Primary: Prevention of Entry Dyspareunia With Non-hormonal Therapy — 5.3; 1.04; NA; 0.57 Units on a scale — p=0.0149

Primary: Tampon Test — -2.43; -1.88 units on a scale

Primary: Visual Analogue Scale — 5.3; 5.8; 5.1; 3.8 score on a scale

Primary: Visual Analog Scale (VAS) for Pain — 50; 39 score on a scale — p=0.62

Primary: Is Vibration Therapy (Through the Use of Handheld External Vibrators on Clitoral and Vulval Area) Acceptable to Women as Part of Medical Management of Vaginismus and…

Primary: Standing Vertigo Intensity — 165.10; 155.10; 136.60 mm*day — p=0.8466

Primary: Change From Baseline in Pain on the Visual Analog Scale (VAS) at Week 12 — -8.5; -7.4 units on a scale — p=0.8979

Primary: Female Sexual Function Index (FSFI) — 16.72; 16.88; 22.02; 21.22 score on a scale

Primary: 6 Weeks - Total FSFI Score — 26.0; 17.4 score on a scale — p=0.109

Primary: Change in Static Subjective Visual Vertical (SVV) — 0.69; 0.58; 0.69; 0.89 degrees — p=0.97

Primary: Change From Baseline in Participant's Self-Assessment of Symptom of Vulvovaginal Atrophy (VVA): Dyspareunia (Pain Associated With Sexual Activity) to Final Assessment…

Primary: Superficial Pelvic Floor Muscle (Bulbospongiosus, Ischiocavernosus, Superficial Transverse Perineal Muscles)Stiffness (kPa) Measured by Shear-wave Elastography — 612…

Primary: Primary Outcome Measure: Percentage of Subjects Improved Global Response Assessment Scale — 4; 3 Participants — p=0.317

Primary: Percent Change in Average Vaginal Pulse Amplitude (VPA) During Stimulation From the Average Baseline Value — 3.3; 3.5 Percent change

Primary: Change in VM-PATHI (Vestibular Migraine-Patient Assessment Tool and Handicap Inventory) Score From Baseline to Month 4 — -14.8; -5.1 score on a scale

Primary: Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear (Dryness Strata) — -3.7; -31.7 percentage of parabasal cells

Primary: Primary Postoperative Pain Measured by the Numerical Rating Scale (NRS) — 3.0; 4.0; 3.75 score on a scale — p=0.39

Primary: Change in Balance Performance — 0.52; 0.42; 0.51; 0.48 degrees per second

Primary: Mean Change From Baseline in the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom (MBS) of Vaginal Dryness — -1.22; -1.26; -0.84 Units on a scale

Primary: Dizziness Handicap Inventory — -12.0; -13.2 score on a scale